AstraZeneca Submits Seroquel XR sNDA For Major Depressive Disorder
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm looks to expand $4 billion franchise into lucrative MDD market.
You may also be interested in...
AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.
AstraZeneca Outlines Two-year Development, Debt Reduction Strategy
Anglo-Swiss pharma reports first quarter sales increases for Seroquel and Crestor; Nexium declines.
FDA Clears Wyeth’s Pristiq For Depression
New study in menopausal hot flashes and night sweats is due first half of this year.